Pulmonary Arterial Hypertension Market Size is Predicted to Garner USD 12 Billion by 2031

As per the report published by Allied Market Research, the global pulmonary arterial hypertension market generated $7.2 billion in 2021, and is expected to reach $12 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031.

The report provides an in-depth analysis of top segments, changing market trends, value chains, key investment pockets, competitive scenarios, and regional landscape. The report is an essential and helpful source of information for leading market players, investors, new entrants, and stakeholders in formulating new strategies for the future and taking steps to strengthen their position in the market.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭- https://www.alliedmarketresearch.com/request-sample/5470

𝐂𝐨𝐯𝐢𝐝-19 𝐬𝐜𝐞𝐧𝐚𝐫𝐢𝐨:
The Covid-19 outbreak positively affected the market due to rise in prevalence of Covid-19 infactions with patients already suffering from pulmonary artery hypertension.
However, the diagnosis and treatment of pulmonary hypertension and observation of elevated mortality risk in individuals severely affected during the pandemic.
The report segments the global pulmonary arterial hypertension market on the basis of drug type, type, route of administration, and region.

Based on drug type, the prostacyclin and prostacyclin analogs segment held the largest share in 2021, accounting for more than half of the market. In addition, the segment is estimated to register the highest CAGR of 5.5% during the forecast period.

On the basis of type, the branded segment dominated the market in terms of revenue in 2021, accounting for more than four-fifths of the market. However, the generics segment is estimated to register the highest CAGR of 5.7% from 2022 to 2031.

Based on route of administration, the oral segment held the largest share in 2021, accounting for nearly two-thirds of the market. In addition, the segment is projected to manifest the highest CAGR of 5.6% during the forecast period.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲- https://www.alliedmarketresearch.com/purchase-enquiry/5470

The global pulmonary arterial hypertension market is analyzed across several regions such as North America, LAMEA, Asia-Pacific, and Europe. The market across North America held the lion's share in 2021, accounting for more than two-fifths of the market. However, the market across Asia-Pacific is expected to register the highest CAGR of 7.2% from 2022 to 2031.

The global pulmonary arterial hypertension market report includes an in-depth analysis of the prime market players such as
Bayer AG,
GlaxoSmithKline Plc,
Gilead Sciences, Inc.,
Johnson & Johnson,
Lupin Pharmaceuticals, Inc.,
Sandoz Inc. (Novartis),
Sun Pharmaceutical Industries, Ltd.,
Teva Pharmaceutical Industries Ltd.,
United Therapeutics Corporation and Viatris Inc.

The report analyzes these key players in the global pulmonary arterial hypertension market. These players have adopted various strategies such as new product launches, expansion, partnerships, and others to increase their market penetration and strengthen their position in the industry. The report is helpful in determining the business performance, operating segments, product portfolio, and developments of every market player.

𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞- https://www.alliedmarketresearch.com/pah-treatment-market

𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐢𝐧 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐃𝐨𝐦𝐚𝐢𝐧-
𝐒𝐚𝐫𝐜𝐨𝐦𝐚 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/sarcoma-drugs-market-A31578

𝐕𝐢𝐭𝐢𝐥𝐢𝐠𝐨 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/vitiligo-treatment-market-A31464

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.